Abstract
Acute Myeloid Leukemia (AML) is a heterogeneous malignancy arising from the malignant transformation of hematopoietic stem cells, characterized by the accumulation of blasts in the myeloid lineage. While common cytogenetic alterations in AML play a critical role in prognostic classification, rare chromosomal translocations may have distinct impacts on disease biology and treatment response. In this report, we present a high-risk AML case harboring the t(1; 19) translocation. By highlighting the diagnostic and therapeutic challenges posed by this uncommon genetic aberration, this case aims to contribute to clinical practice in the field of hematology.